MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Firm”), a professional stage pharmaceutical business committed to prolonging healthy lifespan, today announced that the very first client has actually been enrolled in the Firm’s Phase 2 clinical trial of lead candidate MYMD-1, an oral immune regulatory authority medicine, as a treatment for delaying aging and broadening healthy and balanced life expectancy.
The key endpoint for the Phase 2 double-blind, placebo-controlled professional test is to attain a decrease in the distributing levels of (TNF-α), tumor death factor receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the proteins in the body that cause inflammation and also assist turn on the process of aging. The secondary measures of the test will be the safety, tolerability, and also pharmacokinetics in this populace of patients.
” In a Phase 1 scientific trial of MYMD-1, we demonstrated the medication’s statistically substantial efficiency in decreasing levels of TNF-α, a key player in causing pathological aging, in the blood. The FDA has actually authorized TNF-α reduction as the main endpoint for our Phase 2 study, which our company believe placements us well for a successful Phase 2 end result,” said Chris Chapman, M.D., Head Of State, Director as well as Principal Medical Officer of MyMD. “The initiation of patient registration in this study developments our goal to slow the aging process, stop loss of muscle mass tissue in aging, limit frailty, as well as prolong healthy and balanced life-span.”
MyMD has actually stated that there are no FDA-approved drugs for treating aging problems and prolonging healthy life-span humans, a market anticipated to be at least $600 billion by 20251 according to a major financial investment bank. TNF-α blockers are one of the most recommended medications by earnings, a global market of around $40 billion per year,2 and also, according to Nature Aging journal,3 a stagnation in aging that would certainly boost life span by one year is worth $38 trillion and also by one decade deserves $367 trillion.
In addition to aging, MYMD-1’s unique activity in managing the body immune system and also treating persistent swelling is being developed for the therapy of autoimmune condition, including rheumatoid joint inflammation (RA), numerous sclerosis (MS), diabetes mellitus, and also inflammatory digestive tract disease.
” We plan to start creating methods for a Stage 2 pilot research study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The climbing prevalence of rheumatoid arthritis as well as various other autoimmune as well as inflammatory illness are driving need for TNF preventions like MYMD-1, and we believe our orally administered medicine with very reduced poisoning would be disruptive to the $60 billion market for RA if approved by the FDA for this indicator.”
Rheumatoid arthritis impacts roughly 40 million individuals around the world.4.
Initially established for autoimmune conditions, MYMD-1’s main objective is to slow the aging process, prevent sarcopenia and also frailty, as well as extend healthy and balanced life-span. Because it can cross the blood-brain obstacle as well as access to the main nervous system (CNS), MYMD-1 is also placed to be a feasible therapy for brain-related problems. Its system of activity as well as efficacy in diseases consisting of multiple sclerosis (MS) as well as thyroiditis have actually been studied with collaborations with several academic organizations. MYMD-1 is also showing pledge in pre-clinical researches as a possible treatment for blog post- COVID-19 problems and as an anti-fibrotic as well as anti-proliferation therapeutic.
MYMD-1 has revealed efficiency in pre-clinical studies in managing the immune system by doing as a careful inhibitor of lump necrosis factor-alpha (TNF-α), a motorist of persistent swelling. Unlike other treatments, MYMD-1 has actually been received these pre-clinical studies to selectively block TNF-α when it ends up being overactivated in autoimmune illness as well as cytokine tornados, but not obstruct it from doing its regular work of being an initial -responder to any type of regular sort of moderate infection. MYMD-1’s simplicity of oral application is an additional differentiator contrasted to currently offered TNF-α blockers, every one of which require shipment by injection or infusion. No approved TNF prevention has actually ever before been dosed by mouth. Furthermore, the medicine is not immunosuppressive and also has actually not been revealed to cause the serious adverse effects common with typical treatments that deal with inflammation.
About MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a medical phase pharmaceutical company committed to expanding healthy life expectancy, is focused on developing two unique therapeutic systems that treat the root causes of disease as opposed to just attending to the symptoms. MYMD-1 is a medication platform based on a scientific phase small particle that controls the body immune system to control TNF-α, which drives persistent inflammation, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, increase long life, as well as deal with autoimmune diseases as well as COVID-19- linked depression. The Firm’s second medication system, Supera-CBD, is being established to treat persistent pain, dependency as well as epilepsy. Supera-CBD is an unique artificial by-product of cannabidiol (CBD) and also is being created to attend to and improve upon the quickly growing CBD market, which includes both FDA accepted drugs and also CBD items not currently regulated as medicines. To learn more, check out www.mymd.com.